Statement from the Board of Directors of Procaps Group

Procaps Group (NASDAQ: PROC) ("Procaps"). Having completed the last ordinary meeting of 2023 on December 19th in which Ruben Minski acted as CEO of the Procaps Group for the last time, and taking into account that as of January 15th, 2024 he will take over as Executive Chairman of the Board, which resulted from a planned and communicated process to the market since February of this year, we would like to express our appreciation to Ruben for his inspiring and visionary leadership that has allowed Procaps to be a leading organization in the pharmaceutical sector in the Region today, recognized and valued in the market by the different stakeholders.

Throughout his career in the Organization, Ruben has demonstrated great experience and leadership in managing in a very positive way the Company's growth, as well as navigating moments of difficulty and uncertainty, imbuing the more than 5,000 employees of the Procaps Group with a daring and resilient vision to successfully face the challenges encountered.

In these more than four decades of management, the Organization has achieved major milestones that reflect its position in the international market, such as being the first pharmaceutical company in Latin America to be certified for RX products by the FDA in 2009 and becoming the first Latin American pharmaceutical company to enter Nasdaq in 2021, thus strengthening its commitment to continue generating growth with profitability.

Today, the Procaps Group has a direct presence in 13 countries in the Americas, with production centers in Colombia, Brazil, El Salvador and from 2022 in the United States, which has allowed it to reach more than 50 territories through its different business lines and products.

These are the result of the strategic vision with which the Organization has been led, placing innovation at the center of the business and its organizational culture, with a portfolio of 44 patents granted and 36 pending in different geographies.

Ruben has been a promoter of the organic and inorganic growth of the Organization, which today has a pipeline of more than 100 products under development, more than 3,000 sanitary registrations in force and close to 1,100 in evaluation process at the regulatory entities of the different regions that have positioned the Company as the one with the highest growth within the 10 organizations with the highest market share in the Region and within the 3 most prescribed by the medical body (*). Additionally, the Organization has a systemic M&A program that permanently assesses the best options to add significant value to the Company's shareholders, in order to close profitable and synergic transactions.